Gilbert's Pharma Limited 10497204 true 2024-01-01 2024-12-31 2024-12-31 The principal activity of the company is that of a retail pharmacy up unitl 30 September 2022, when the company sold its trade and assets. Since the disposal of the trade and assets, the company has continued to receive and pay any remaining balances. Digita Accounts Production Advanced 6.30.9574.0 true Mr D Gilbert false 10497204 2024-01-01 2024-12-31 10497204 2024-12-31 10497204 core:RetainedEarningsAccumulatedLosses 2024-12-31 10497204 core:ShareCapital 2024-12-31 10497204 core:CurrentFinancialInstruments 2024-12-31 10497204 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 10497204 bus:FRS102 2024-01-01 2024-12-31 10497204 bus:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 10497204 bus:FullAccounts 2024-01-01 2024-12-31 10497204 bus:RegisteredOffice 2024-01-01 2024-12-31 10497204 bus:Director1 2024-01-01 2024-12-31 10497204 bus:EntityNoLongerTradingButTradedInPast 2024-01-01 2024-12-31 10497204 bus:Consolidated 2024-01-01 2024-12-31 10497204 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 10497204 core:Goodwill 2024-01-01 2024-12-31 10497204 core:FurnitureFittingsToolsEquipment 2024-01-01 2024-12-31 10497204 core:LandBuildings 2024-01-01 2024-12-31 10497204 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2024-01-01 2024-12-31 10497204 countries:EnglandWales 2024-01-01 2024-12-31 10497204 2023-01-01 2023-12-31 10497204 2023-12-31 10497204 core:RetainedEarningsAccumulatedLosses 2023-12-31 10497204 core:ShareCapital 2023-12-31 10497204 core:CurrentFinancialInstruments 2023-12-31 10497204 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 iso4217:GBP xbrli:pure

Registration number: 10497204

The option to file Filleted Accounts has been selected.
Please correct this via the Summary tab within the General section.

Gilbert's Pharma Limited

Annual Report and Unaudited Financial Statements

for the Year Ended 31 December 2024

 

Gilbert's Pharma Limited

Contents

Balance Sheet

1

Notes to the Unaudited Financial Statements

2 to 5

 

Gilbert's Pharma Limited

(Registration number: 10497204)
Balance Sheet as at 31 December 2024

Note

2024
£

2023
£

Fixed assets

 

Investments

4

7,500

7,500

Current assets

 

Debtors

5

-

27,600

Cash at bank and in hand

 

-

2,322

 

-

29,922

Creditors: Amounts falling due within one year

6

(358,600)

(388,522)

Net current liabilities

 

(358,600)

(358,600)

Net liabilities

 

(351,100)

(351,100)

Capital and reserves

 

Called up share capital

100

100

Retained earnings

(351,200)

(351,200)

Shareholders' deficit

 

(351,100)

(351,100)

For the financial year ending 31 December 2024 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

Approved and authorised by the director on 12 September 2025
 


Mr D Gilbert
Director

 

Gilbert's Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
C/O Hazlewoods LLP
Staverton Court
Staverton
Cheltenham
Gloucestershire
GL51 0UX
United Kingdom

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except for, where disclosed in these accounting policies, certain items that are shown at fair value.

The presentational currency of the financial statements is Pounds Sterling, being the functional currency of the primary economic environment in which the company operates. Monetary amounts in these financial statements are rounded to the nearest Pound.

Going concern

The company ceased to trade on 30 September 2022 when the trade and assets were sold and there are no plans to recommence trading in the future. Accordingly, the directors do not consider it appropriate to prepare the financial statements on a going concern basis. This includes, where applicable, writing the company's assets down to their net realisable value and making provisions against contracts that have become onerous at the reporting date. No material adjustments arose as a result of ceasing to apply the going concern basis.

Judgements

No significant judgements have been made by management in preparing these financial statements.

Key sources of estimation uncertainty

No key sources of estimation uncertainty have been identified by management in preparing these financial statements other than those detailed in these accounting policies..

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Leasehold land and buildings

Over the life of the lease

Furniture, fittings and equipment

15% on a reducing balance basis

 

Gilbert's Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

Goodwill

Goodwill is amortised over its useful life, which is estimated by the directors at 20 years.

Intangible assets

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Goodwill

5% Straight line

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.


Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. All trade debtors are repayable within one year and hence are included at the undiscounted cost of cash expected to be received. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the debtors.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and all are repayable within one year and hence are included at the undiscounted amount of cash expected to be paid.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

 

Gilbert's Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Financial instruments

Classification
Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.
 Recognition and measurement
All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.
 Impairment
Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss as described below.

A non financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 0 (2023 - 0).

4

Investments

2024
£

2023
£

Other investments

7,500

7,500

5

Debtors

2024
£

2023
£

Other debtors

-

27,600

-

27,600

 

Gilbert's Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

6

Creditors

Note

2024
£

2023
£

Due within one year

 

Loans and borrowings

7

358,600

348,229

Trade creditors

 

-

2,338

Social security and other taxes

 

-

20,345

Other payables

 

-

15,125

Accruals

 

-

2,485

 

358,600

388,522

7

Loans and borrowings

Current loans and borrowings

2024
£

2023
£

Other borrowings

358,600

348,229

8

Related party transactions

Summary of transactions with key management

Key management personnel are considered to be the directors of the company.
As at the balance sheet date, the company owed the director £348,229 (2023 - £348,229). There are no fixed repayment terms and no interest is charged on the loan.